Welcome Italia selects ADVA FSP 3000 for ultra-high-capacity enterprise services
30.7.2019 09:55:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Welcome Italia has selected its FSP 3000 and ALM fiber monitoring solution to enable assured high-capacity enterprise services throughout Italy. The technology partnership will create scalable fiber optic infrastructure and provide the security and reliability needed for IoT and 5G applications. Stretching over 2,500km and connecting Welcome Italia’s two main data centers, the new network features ADVA’s colorless, directionless and flexgrid multi-degree ROADMs, enabling automatic traffic rerouting for enhanced availability. The solution has also been primed for the comprehensive, low-latency security of ADVA’s ConnectGuard™ Optical encryption technology. ADVA’s partner Sirti is installing the network and will also provide ongoing maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190729005500/en/
Image ADVA's FSP 3000 and ALM fiber monitoring solution will play a key role in delivering assured high-capacity enterprise services throughout Italy (Photo: Business Wire)
”Our aim is to harness the best technology available to provide the ultimate service for our enterprise customers. ADVA’s scalable and efficient solution not only empowers us to deliver fast, flexible and secure business continuity services, but it also helps us reduce cost and lay the foundation for future growth,” commented Nicola Gallico, network manager and founder, Welcome Italia. “This deployment provides concrete answers to the most urgent needs of Italian enterprises. It means they can rely on high-speed, low-latency connectivity backed up by a fully redundant network architecture and protected by real-time fiber monitoring. With the support of the ADVA and Sirti team, we’ll continue to help our customers develop their businesses and seize new opportunities.”
Welcome Italia’s new backbone network serves enterprise clients throughout Italy with points of presence spread across the country. Built on the ADVA FSP 3000, it simplifies network operations and helps to reduce capital and operational expenditure. With its modular architecture, the FSP 3000 gives Welcome Italia the freedom to expand its network as soon as it’s required. The solution is also monitored by the ADVA ALM, which gives real-time insight into the integrity and performance of Welcome Italia’s fiber infrastructure, significantly improving robustness and efficiency. What’s more, the complete network is managed by Ensemble Controller, which combines efficiency in manual operations with programmatic control. This advanced management and domain control solution supports users while also enabling intelligent algorithms to gather data and take autonomous action.
“Welcome Italia chose our technology because it’s the ideal tool for meeting the needs of enterprise customers. It provides superb scalability and cost efficiency, enabling high-speed services that are secure and fully future proof. We’re pleased to be working closely with Welcome Italia’s team to ensure that businesses in this region can capitalize on the most advanced latency-sensitive applications as soon as they hit the market,” commented Marcello Forti, VP, sales, ADVA. “With the flexibility of our ROADM technology and our ALM providing complete fiber network visibility, this solution gives Welcome Italia a new level of agility and reliability. For enterprises across Italy, Welcome Italia’s new network will be the key to harnessing the business opportunities of the IoT.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.
About Welcome Italia
Welcome Italia is an Italian telecommunication operator that simplifies your company’s communications with an integrated offer of mobile and fixed line services called Vianova. Vianova combines traditional services, like telephony and ultra-broadband data access, with unified communication and collaboration services like cloud, centrex, mail, meetings, Wi-Fi calls, busy calls, SIM manager. Welcome Italia is also appreciated for the quality of its customer care that answers calls in three rings. Two property data centers host the redundant infrastructure that allows the supply of services for the whole Welcome Italia Group. www.welcomeitalia.it/en
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190729005500/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
